Table 2 Characteristics of hospitalizations due to IBD exacerbation and those due to therapy-related adverse events
From: Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD
Characteristic | Hospitalizations due to IBD exacerbations n = 194 | Hospitalizations due to therapy-related adverse events n = 24 | p |
|---|---|---|---|
Age (year) | 14.9 (11.6–16.5) | 16.2 (13.3–17.1) | 0.277 |
Males, n | 93 (47.9%) | 9 (37.5%) | 0.439 |
Crohn’s disease | 131 (67.5%) | 16 (66.7%) | 0.944 |
Ulcerative colitis | 63 (32.5%) | 8 (33.3%) | |
Duration from IBD diagnosis (year) | 2.4 (0.7–4.3) | 1.6 (0.4–4.2) | 0.801 |
Therapy at admission | |||
5-ASA | 101 (52.1%) | 17 (70.8%) | 0.082 |
Corticosteroids | 40 (20.6%) | 6 (25%) | 0.619 |
Enteral nutrition | 40 (20.6%) | 4 (16.7%) | 0.649 |
Methotrexate | 5 (2.6%) | 0 | > 0.999 |
Azathioprine | 69 (35.6%) | 13 (54.2%) | 0.116 |
Biologic agents | 49 (25.3%) | 7 (29.2%) | 0.679 |
Disease activity at admission | < 0.001 | ||
Remission | 0 | 7 (29.2%) | |
Mild | 104 (47.5%) | 13 (54.2%) | |
Moderate | 85 (38.8%) | 4 (16.6%) | |
Severe | 30 (13.7%) | 0 | |
Length of hospitalization | 4 (2–6.3) | 6 (3–9) | 0.934 |
Blood cultures | 88 (45.4%) | 14 (58.3%) | 0.299 |
Stool culture | 54 (27.8%) | 6 (25%) | 0.746 |
Imaging studies | 129 (66.5%) | 19 (79.2%) | 0.243 |
US | 69 (35.6%) | 13 (54.2%) | 0.125 |
CT | 22 (11.3%) | 1 (4.2%) | 0.312 |
MRI | 3 (1.5%) | 0 | > 0.999 |
Endoscopy | |||
Upper GI endoscopy | 17 (8.7%) | 2 (8.4%) | 0.942 |
Lower GI endoscopy | 26 (13.4%) | 1 (4.2%) | 0.229 |
Antibiotics | 98 (50.5%) | 11 (45.8%) | 0.709 |
Blood transfusion | 13 (6.7%) | 1 (4.2%) | 0.601 |
Surgery | 14 (7.2%) | 0 | 0.374 |
Abscess drainage | 10 (5.2%) | ||
Ileo-cecectomy | 1 (0.5%) | ||
Others | 3 (1.5%) | ||